Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN (BC): Producer improves GMP stability programs

HYTN Innovations shares they have made advancements with their Good Manufacturing Practice (GMP) stability programs.

Stability programs constitute a cornerstone of all GMP guidelines and are vital for achieving GMP certification. Since achieving GMP certification under the International Pharmaceutical Cooperation Scheme (PIC/S) and welcoming Health Canada for a GMP audit of their Kelowna facility, HYTN has expanded its stability program. Notably, this expansion encompasses both 10g jars and bags for cannabis products and 1g sachets of psilocybin-containing mushrooms, marking a significant milestone that reflects HYTN's comprehensive commitment to product excellence, consumer safety, and innovation, all while maintaining our rigorous dedication to quality assurance.

HYTN notes that for its GMP cannabis products, it currently has data to support a shelf life of six months for items in bags and one year for those in jars. The rapid results are thanks in part to stability data received from HYTN's Australian partners, Promethean Biopharma. HYTN expects that stability data for bagged products will support a 12-month shelf life prior to releasing its first finished products for international export.

Furthermore, HYTN believes that its vertically integrated cultivation, harvest, fabrication, packaging, labeling, and stability program for psilocybin-containing mushroom products stands as a first-of-its-kind initiative within the Canadian GMP manufacturing landscape. This program underscores HYTN's dedication to innovation and demonstrates the robustness and value of the Company's Quality Management System. While data collection is ongoing, HYTN aims to provide critical stability data for the inclusion of its products in various clinical applications and to set industry benchmarks in the GMP processing of psilocybin and other tryptamine derivatives from mushrooms.

Jason Broome, HYTN's Chief Operations Officer, shared his enthusiasm for the advancements, "The strides we've made in our GMP stability programs are not just technical achievements; they reflect our unwavering commitment to innovation and quality in every product we bring to market. As we pioneer psychoactive compound production, we remain dedicated to setting the gold standard for the industry. We're excited to delve deeper into the implications of our progress during our upcoming quarterly management discussions, where we'll map out the next phases of our journey and further solidify our leadership position."

For more information:

Publication date: